Taguchi Y-H, Turki Turki
Department of Physics, Chuo University, 1-13-27 Kasuga, Bunkyo-ku, Tokyo, 112-8551, Japan.
Department of Computer Science, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
BMC Bioinformatics. 2024 Dec 18;25(1):377. doi: 10.1186/s12859-024-06009-9.
The evaluation of drug-gene-disease interactions is key for the identification of drugs effective against disease. However, at present, drugs that are effective against genes that are critical for disease are difficult to identify. Following a disease-centric approach, there is a need to identify genes critical to disease function and find drugs that are effective against them. By contrast, following a drug-centric approach comprises identifying the genes targeted by drugs, and then the diseases in which the identified genes are critical. Both of these processes are complex. Using a gene-centric approach, whereby we identify genes that are effective against the disease and can be targeted by drugs, is much easier. However, how such sets of genes can be identified without specifying either the target diseases or drugs is not known. In this study, a novel artificial intelligence-based approach that employs unsupervised methods and identifies genes without specifying neither diseases nor drugs is presented. To evaluate its feasibility, we applied tensor decomposition (TD)-based unsupervised feature extraction (FE) to perform drug repositioning from protein-protein interactions (PPI) without any other information. Proteins selected by TD-based unsupervised FE include many genes related to cancers, as well as drugs that target the selected proteins. Thus, we were able to identify cancer drugs using only PPI. Because the selected proteins had more interactions, we replaced the selected proteins with hub proteins and found that hub proteins themselves could be used for drug repositioning. In contrast to hub proteins, which can only identify cancer drugs, TD-based unsupervised FE enables the identification of drugs for other diseases. In addition, TD-based unsupervised FE can be used to identify drugs that are effective in in vivo experiments, which is difficult when hub proteins are used. In conclusion, TD-based unsupervised FE is a useful tool for drug repositioning using only PPI without other information.
药物 - 基因 - 疾病相互作用的评估是识别有效治疗疾病药物的关键。然而,目前难以确定对疾病关键基因有效的药物。遵循以疾病为中心的方法,需要识别对疾病功能至关重要的基因,并找到对其有效的药物。相比之下,以药物为中心的方法包括识别药物靶向的基因,然后确定所识别基因在其中起关键作用的疾病。这两个过程都很复杂。采用以基因为中心的方法,即识别对疾病有效且可被药物靶向的基因,要容易得多。然而,如何在不指定目标疾病或药物的情况下识别这类基因尚不清楚。在本研究中,提出了一种基于人工智能的新方法,该方法采用无监督方法,在不指定疾病和药物的情况下识别基因。为了评估其可行性,我们应用基于张量分解(TD)的无监督特征提取(FE),在没有任何其他信息的情况下从蛋白质 - 蛋白质相互作用(PPI)中进行药物重新定位。基于TD的无监督FE选择的蛋白质包括许多与癌症相关的基因,以及靶向所选蛋白质的药物。因此,我们仅使用PPI就能识别出癌症药物。由于所选蛋白质具有更多相互作用,我们用枢纽蛋白取代所选蛋白质,发现枢纽蛋白本身可用于药物重新定位。与只能识别癌症药物的枢纽蛋白不同,基于TD的无监督FE能够识别用于其他疾病的药物。此外,基于TD的无监督FE可用于识别在体内实验中有效的药物,而使用枢纽蛋白时很难做到这一点。总之,基于TD的无监督FE是一种仅使用PPI且无其他信息进行药物重新定位的有用工具。